Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.

Lilly said its drug showed no signs of liver ... Some patients like the idea of just a weekly shot, said Dr. Rudolph Leibel, a diabetes and obesity expert at Columbia University.

From my colleague Elaine Chen: Eli Lilly’s stock shot up 14% yesterday, after the pharma giant reported the first Phase 3 results of its GLP-1 pill orforglipron. The small molecule helped ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

The triumph of Ozempic, the blockbuster diabetes shot from Novo Nordisk A/S, and related drugs including Zepbound and Mounjaro from Lilly, has set off an all-out push to develop a pill that’s ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

The medication — orforglipron from pharmaceutical giant Eli Lilly — is in the same class of drugs as Mounjaro and Ozempic, which patients self-inject once a week. In contrast, the pill is ...